Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Pancreatic Carcinoma|Melanoma|Endometrial Carcinoma
Interventions: DRUG: MCS110|DRUG: PDR001
Sponsor: Novartis Pharmaceuticals